COVID-19 Impact on Global Alpha- Antitrypsin Deficiency Treatment Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 CT-2009
  • 1.4.3 POL-6014
  • 1.4.4 ARO-AAT
  • 1.4.5 ALNAAT-02
  • 1.4.6 Others
• 1.5 Market by Application
  • 1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Alpha- Antitrypsin Deficiency Treatment Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Alpha- Antitrypsin Deficiency Treatment Industry
    • 1.6.1.1 Alpha- Antitrypsin Deficiency Treatment Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Alpha- Antitrypsin Deficiency Treatment Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Alpha- Antitrypsin Deficiency Treatment Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Alpha- Antitrypsin Deficiency Treatment Market Perspective (2015-2026)
• 2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Regions
  • 2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020)
  • 2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Alpha- Antitrypsin Deficiency Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Market Size
  • 3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2015-2020)
  • 3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
  • 3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
• 3.3 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
• 3.4 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
• 3.5 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020)
• 4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026)

5 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Application (2015-2026)

• 5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
• 5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 6.2 Alpha- Antitrypsin Deficiency Treatment Key Players in North America (2019-2020)
• 6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 7.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020)
• 7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

8 China

• 8.1 China Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 8.2 Alpha- Antitrypsin Deficiency Treatment Key Players in China (2019-2020)
• 8.3 China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 8.4 China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 9.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020)
• 9.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 9.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 10.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 10.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

11 India

• 11.1 India Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 11.2 Alpha- Antitrypsin Deficiency Treatment Key Players in India (2019-2020)
• 11.3 India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 11.4 India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
• 12.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
• 12.4 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Adverum Biotechnologies, Inc.
  • 13.1.1 Adverum Biotechnologies, Inc. Company Details
  • 13.1.2 Adverum Biotechnologies, Inc. Business Overview and Its Total Revenue
  • 13.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020))
  • 13.1.5 Adverum Biotechnologies, Inc. Recent Development
• 13.2 Alnylam Pharmaceuticals, Inc.
  • 13.2.1 Alnylam Pharmaceuticals, Inc. Company Details
  • 13.2.2 Alnylam Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  • 13.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
• 13.3 Applied Genetic Technologies Corporation
  • 13.3.1 Applied Genetic Technologies Corporation Company Details
  • 13.3.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue
  • 13.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.3.5 Applied Genetic Technologies Corporation Recent Development
• 13.4 Arrowhead Pharmaceuticals, Inc.
  • 13.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
  • 13.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  • 13.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
• 13.5 Carolus Therapeutics, Inc.
  • 13.5.1 Carolus Therapeutics, Inc. Company Details
  • 13.5.2 Carolus Therapeutics, Inc. Business Overview and Its Total Revenue
  • 13.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.5.5 Carolus Therapeutics, Inc. Recent Development
• 13.6 Cevec Pharmaceuticals GmbH
  • 13.6.1 Cevec Pharmaceuticals GmbH Company Details
  • 13.6.2 Cevec Pharmaceuticals GmbH Business Overview and Its Total Revenue
  • 13.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.6.5 Cevec Pharmaceuticals GmbH Recent Development
• 13.7 Dicerna Pharmaceuticals, Inc.
  • 13.7.1 Dicerna Pharmaceuticals, Inc. Company Details
  • 13.7.2 Dicerna Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  • 13.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
• 13.8 Digna Biotech, S.L.
  • 13.8.1 Digna Biotech, S.L. Company Details
  • 13.8.2 Digna Biotech, S.L. Business Overview and Its Total Revenue
  • 13.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.8.5 Digna Biotech, S.L. Recent Development
• 13.9 Editas Medicine, Inc.
  • 13.9.1 Editas Medicine, Inc. Company Details
  • 13.9.2 Editas Medicine, Inc. Business Overview and Its Total Revenue
  • 13.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.9.5 Editas Medicine, Inc. Recent Development
• 13.10 Grifols, S.A.
  • 13.10.1 Grifols, S.A. Company Details
  • 13.10.2 Grifols, S.A. Business Overview and Its Total Revenue
  • 13.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 13.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 13.10.5 Grifols, S.A. Recent Development
• 13.11 Inhibrx
  • 10.11.1 Inhibrx Company Details
  • 10.11.2 Inhibrx Business Overview and Its Total Revenue
  • 10.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.11.5 Inhibrx Recent Development
• 13.12 Intellia Therapeutics, Inc.
  • 10.12.1 Intellia Therapeutics, Inc. Company Details
  • 10.12.2 Intellia Therapeutics, Inc. Business Overview and Its Total Revenue
  • 10.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.12.5 Intellia Therapeutics, Inc. Recent Development
• 13.13 International Stem Cell Corporation
  • 10.13.1 International Stem Cell Corporation Company Details
  • 10.13.2 International Stem Cell Corporation Business Overview and Its Total Revenue
  • 10.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.13.5 International Stem Cell Corporation Recent Development
• 13.14 Ionis Pharmaceuticals, Inc.
  • 10.14.1 Ionis Pharmaceuticals, Inc. Company Details
  • 10.14.2 Ionis Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  • 10.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.14.5 Ionis Pharmaceuticals, Inc. Recent Development
• 13.15 Kamada Ltd.
  • 10.15.1 Kamada Ltd. Company Details
  • 10.15.2 Kamada Ltd. Business Overview and Its Total Revenue
  • 10.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.15.5 Kamada Ltd. Recent Development
• 13.16 Polyphor Ltd.
  • 10.16.1 Polyphor Ltd. Company Details
  • 10.16.2 Polyphor Ltd. Business Overview and Its Total Revenue
  • 10.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.16.5 Polyphor Ltd. Recent Development
• 13.17 ProMetic Life Sciences Inc.
  • 10.17.1 ProMetic Life Sciences Inc. Company Details
  • 10.17.2 ProMetic Life Sciences Inc. Business Overview and Its Total Revenue
  • 10.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.17.5 ProMetic Life Sciences Inc. Recent Development
• 13.18 rEVO Biologics, Inc.
  • 10.18.1 rEVO Biologics, Inc. Company Details
  • 10.18.2 rEVO Biologics, Inc. Business Overview and Its Total Revenue
  • 10.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.18.5 rEVO Biologics, Inc. Recent Development
• 13.19 Sangamo BioSciences, Inc.
  • 10.19.1 Sangamo BioSciences, Inc. Company Details
  • 10.19.2 Sangamo BioSciences, Inc. Business Overview and Its Total Revenue
  • 10.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
  • 10.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
  • 10.19.5 Sangamo BioSciences, Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer